The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.

Bibliographic Details
Title: The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
Authors: Takeshita, Emiko, Ishibashi, Keiichiro, Koda, Keiji, Oda, Noritaka, Yoshimatsu, Kazuhiko, Sato, Yu, Oya, Masatoshi, Yamaguchi, Satoru, Nakajima, Hideo, Momma, Tomoyuki, Maekawa, Hiroshi, Tsubaki, Masahiro, Yamada, Takeshi, Kobayashi, Michiya, Tanakaya, Kohji, Ishida, Hideyuki
Source: Surgery Today; Aug2021, Vol. 51 Issue 8, p1309-1319, 11p
Subject Terms: OVERALL survival, COLON cancer, NEUROTOXICOLOGY, ADJUVANT chemotherapy, JAPANESE people
Abstract: Purpose: We previously reported the first evidence of oncological benefits from a Japanese phase II trial of oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (the FACOS study). We herein report the long-term survival and persistent oxaliplatin-related peripheral sensory neuropathy (PSN) for patients enrolled in this trial. Methods: Patients were scheduled to receive the mFOLFOX6 or CAPOX regimen in the adjuvant setting. The five-year overall survival (OS) rate and persistent PSN were evaluated. Results: A total of 130 patients (mFOLFOX6, n = 73; CAPOX, n = 57) were eligible. The 5-year OS rate was 91.4%. No significant difference in the OS rate was observed between regimens (mFOLFOX6, 94.4%; CAPOX, 87.4%; P = 0.25). The incidence of PSN during adjuvant treatment was 55.4% in grade 1 (G1), 30.0% in G2, and 4.6% in G3. No patients showed G3 PSN at 12 months, but G1 or G2 residual PSN after 5 years was observed in 21.8% (G1, 20%; G2, 1.8%). Conclusions: Updated results from the FACOS study support the benefits of oxaliplatin-based adjuvant chemotherapy in terms of the long-term survival among Japanese patients with stage III colon cancer. However, long-term persistent PSN occurs in about 20% of survivors, counterbalancing the favorable OS. [ABSTRACT FROM AUTHOR]
Copyright of Surgery Today is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
More Details
ISSN:09411291
DOI:10.1007/s00595-021-02230-8
Published in:Surgery Today
Language:English